文献速递认知障碍与痴呆

2型糖尿病患者数十年血糖控制与痴呆风险

Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 Diabetes.
PubMed 文献 · JAMA Neurol · 2023-01-01

该队列研究纳入253 211例50岁及以上2型糖尿病患者,分析不同糖化血红蛋白(HbA1c)累积暴露范围与痴呆风险的关系。结果显示,累积HbA1c≥9%者痴呆风险最高,而HbA1c<8%者风险较低,支持目前推荐的老年2型糖尿病患者宽松血糖目标。

要点

  • 累积HbA1c≥9%的2型糖尿病患者痴呆风险最高。
  • 累积HbA1c<8%与较低的痴呆风险相关。
  • 结果支持目前推荐的老年2型糖尿病患者宽松血糖目标。

核心结论

  • 在该研究中,累积HbA1c≥9%的成人痴呆风险最高,结果支持目前推荐的老年2型糖尿病患者宽松血糖目标。

研究设计与样本

  • 这是一项队列研究,纳入Kaiser Permanente Northern California整合医疗系统成员中50岁及以上的2型糖尿病患者,研究期为1996年1月1日至2015年9月30日,排除了研究期间HbA1c测量少于2次、基线时已有痴呆或随访不足3年者,数据分析于2020年2月至2023年1月进行。

主要发现

  • 共纳入253 211例参与者,平均(SD)年龄61.5(9.4)岁,53.1%为男性,平均(SD)随访时间5.9(4.5)年。
  • 与HbA1c 9%至<10%或≥10%的测量比例≤50%者相比,测量比例>50%者痴呆风险更高(HbA1c 9%至<10%:aHR 1.31 [95% CI, 1.15-1.51];HbA1c≥10%:aHR 1.74 [95% CI, 1.62-1.86])。
  • 与相应类别测量比例≤50%者相比,HbA1c<6%、6%至<7%、7%至<8%的测量比例>50%者痴呆风险更低(HbA1c<6%:aHR 0.92 [95% CI, 0.88-0.97];HbA1c 6%至<7%:aHR 0.79 [95% CI, 0.77-0.81];HbA1c 7%至<8%:aHR 0.93 [95% CI, 0.89-0.97])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The levels of glycemic control associated with the lowest risk of dementia in people with type 2 diabetes are unknown. This knowledge is critical to inform patient-centered glycemic target setting. OBJECTIVE: To examine the associations between cumulative exposure to various ranges of glycated hemoglobin (HbA1c) concentrations with dementia risk across sex and racial and ethnic groups and the association of current therapeutic glycemic targets with dementia risk. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included members of the Kaiser Permanente Northern California integrated health care system with type 2 diabetes who were aged 50 years or older during the study period from January 1, 1996, to September 30, 2015. Individuals with fewer than 2 HbA1c measurements during the study period, prevalent dementia at baseline, or less than 3 years of follow-up were excluded. Data were analyzed from February 2020 to January 2023. EXPOSURES: Time-updated cumulative exposure to HbA1c thresholds. At each HbA1c measurement, participants were categorized based on the percentage of their HbA1c measurements that fell into the following categories: less than 6%, 6% to less than 7%, 7% to less than 8%, 8% to less than 9%, 9% to less than 10%, and 10% or more of total hemoglobin (to convert percentage of total hemoglobin to proportion of total hemoglobin, multiply by 0.01). MAIN OUTCOMES AND MEASURES: Dementia diagnosis was identified using International Classification of Diseases, Ninth Revision codes from inpatient and outpatient encounters. Cox proportional hazards regression models estimated the association of time-varying cumulative glycemic exposure with dementia, adjusting for age, race and ethnicity, baseline health conditions, and number of HbA1c measurements. RESULTS: A total of 253 211 participants were included. The mean (SD) age of participants was 61.5 (9.4) years, and 53.1% were men. The mean (SD) duration of follow-up was 5.9 (4.5) years. Participants with more than 50% of HbA1c measurements at 9% to less than 10% or 10% or more had greater risk of dementia compared with those who had 50% or less of measurements in those categories (HbA1c 9% to <10%: adjusted hazard ratio [aHR], 1.31 [95% CI, 1.15-1.51]; HbA1c≥10%: aHR, 1.74 [95% CI, 1.62-1.86]). By contrast, participants with more than 50% of HbA1c concentrations less than 6%, 6% to less than 7%, or 7% to less than 8% had lower risk of dementia (HbA1c<6%: aHR, 0.92 [95% CI, 0.88-0.97]; HbA1c 6% to <7%: aHR, 0.79 [95% CI, 0.77-0.81]; HbA1c 7% to <8%: aHR, 0.93 [95% CI, 0.89-0.97]). CONCLUSIONS AND RELEVANCE: In this study dementia risk was greatest among adults with cumulative HbA1c concentrations of 9% or more. These results support currently recommended relaxed glycemic targets for older people with type 2 diabetes.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Moran C, Lacy ME, Whitmer RA, et al. Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 Diabetes. JAMA Neurol. 2023. PMID: 37067815. doi:10.1001/jamaneurol.2023.0697

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。